Dr Faiza Zafar, Dr Rahat Abbas, Dr Iqra Afzal.
In the last decades, the understanding and knowledge regarding the intrahepatic cholangiocarcinoma (iCCA) and hepatocellular carcinoma (HCC) has been improved. Scientific research has made it possible to diagnose the liver cancer at the molecular level and provide optimal treatment to the patients to a maximum extent. The initial step, which is considered a landmark for future liver cancer management, was the discovery of TP53 hotspot mutation. In a nutshell, while decades ago the field of liver cancer was perplexing with grim perspectives, limited clinical data and research trials, it has now evolved into a competitive field with multiple advancements, research work and trials based evidence at a constant rate. Positive outcomes in preventive approaches, eliminating risk factors, understanding molecular mechanism, and better treatment chemistry will further increase the status of this field, and it might will exclude liver cancer from top 5 cancer killers.